β-Elemene is reported to enhance the sensitivity of resistant ovarian cancer cells to cisplatin by downregulating excision repair cross-complementation group-1 (ERCC-1) and X-linked inhibitor of apoptotic protein (XIAP) and inactivating c-Jun NH2-terminal kinase (JNK). The gene discussed is ERCC1; the disease is ovarian carcinoma.